MMV support to projects may include financial, in-kind, and advisory activities.
Legend
Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing.

Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ.
WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers.
Paediatric formulation.
Via a bioequivalence study.
Brand names:
1 Coartem® Dispersible
2 Artesun®
3 Larinate® 60mg
4 Eurartesim®
5 Pyramax® tablets or granules
6 ASAQ Winthrop®
7 SPAQ-COTM
8 Supyra®
9 100mg Artesunate Rectocaps
10 ArtecapTM
11 Kozenis/Krintafel (Trademarks owned or licensed by GSK)
Target Product Profiles indicated by bars at the bottom of each coumpound box
____ 3-day cure, artemisinin-based combination therapies (TPP-1)
____ Uncomplicated malaria treatments for single-exposure radical cure (SERC) and/ or resistance management (TPP-1)
____ Severe malaria treatment/ pre-referral intervention (TPP-1)
____ Intermittent preventative treatment (TPP-1)
____ Products targeting prevention of relapse for P. vivax (TPP-1)
____ Prophylaxis (TPP-2)
Target Candidate Profiles activities for each individual molecule, indicated by symbols added to compounds in the translational or product development portfolio

Asexual blood stages

Relapse prevention

Transmission reduction

Causal prophylaxis